Philadelphia-based Minaris Regenerative Medicine, a cell and gene therapies company, the U.S. and U.K. operations of Philadelphia-based WuXi Advanced Therapies, a cell therapy company, and New York-based Altaris, an investment firm, have been combined to form Philadelphia-based Minaris Advanced Therapies, a global cell therapy contract development and manufacturing organization (CDMO) and testing partner.
“Minaris Advanced Therapies is designed to help the industry treat more patients by providing the experience, global footprint, and platforms to accelerate timelines and enable commercialization,” Dr. Eytan Abraham, Minaris Advanced Therapies chief commercial and technology officer, said. “Many of the technologies needed to reduce cost of goods sold and improve turnaround time already exist, we will drive their adoption and implementation at scale.”
The new company will focus on cell and gene therapies. It owns more than 730,000-square-feet with six facilities on three continents and employs more than 1,400 people.
The company brings together more than 40 years of experience in biosafety testing and product characterization and more than 25 years of cell therapy CDMO experience. It provides testing services for more than 27 commercial products and manufactures two commercial cell therapies.
Capabilities include development and manufacturing of cell therapies and viral vectors, innovative platforms, and extensive testing services.